The online version of this article (doi:10.1186/1758-5996-6-80) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
MBG and CAN contributed equally analyzing the data and writing the manuscript. Both authors read and approved the final manuscript.
Alpha-lipoic acid is a naturally occurring substance, essential for the function of different enzymes that take part in mitochondria’s oxidative metabolism. It is believed that alpha-lipoic acid or its reduced form, dihydrolipoic acid have many biochemical functions acting as biological antioxidants, as metal chelators, reducers of the oxidized forms of other antioxidant agents such as vitamin C and E, and modulator of the signaling transduction of several pathways. These above-mentioned actions have been shown in experimental studies emphasizing the use of alpha-lipoic acid as a potential therapeutic agent for many chronic diseases with great epidemiological as well economic and social impact such as brain diseases and cognitive dysfunctions like Alzheimer disease, obesity, nonalcoholic fatty liver disease, burning mouth syndrome, cardiovascular disease, hypertension, some types of cancer, glaucoma and osteoporosis. Many conflicting data have been found concerning the clinical use of alpha-lipoic acid in the treatment of diabetes and of diabetes-related chronic complications such as retinopathy, nephropathy, neuropathy, wound healing and diabetic cardiovascular autonomic neuropathy. The most frequent clinical condition in which alpha-lipoic acid has been studied was in the management of diabetic peripheral neuropathy in patients with type 1 as well type 2 diabetes. Considering that oxidative stress, a imbalance between pro and antioxidants with excessive production of reactive oxygen species, is a factor in the development of many diseases and that alpha-lipoic acid, a natural thiol antioxidant, has been shown to have beneficial effects on oxidative stress parameters in various tissues we wrote this article in order to make an up-to-date review of current thinking regarding alpha-lipoic acid and its use as an antioxidant drug therapy for a myriad of diseases that could have potential benefits from its use.
Snell EE, Strong FM, Peterson WH: Growth factor for bacteria.VI Fractionation and properties of an accessory factor for lactic acid bacteria. Bichem J. 1937, 31: 1789-1799.
Bock E, Schneeweiss J: Ein Beitrag zur Therapie der neuropathia diabetic. Munchner Med Wochenschrift. 1959, 43: 1911-1912.
Moreira PI, Harris PLR, Zhu X, Santos MS, Oliveira CR, Smith MA, Perry G: Lipoic acidi and n-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. J Alzheimers Dis. 2007, 12: 195-206. PubMed
McLain AL, Cormier PJ, Kinter M, Szweda LI: Glutathionylation of α-ketoglutarate dehydrogenase: the chemical nature and relative susceptibility of the cofactor lipoic acid to modification. Free Radic Biol Med. 2013, 61C: 161-169. CrossRef
A-Vadlapudi AD, Vadlapatla RK, Mitra AK: Sodium dependent multivitamin transporter (SMVT): a potential target for drug delivery. Curr Drug Targets. 2012, 13: 994-1003. CrossRef
Trujillo M, Radi R: Peroxynitrite reaction with the reduced and the oxidized forms of lipoic acid: new insights into the reaction of peroxynitrite with thiols. Arch of Biochem and Biophys. 2002, 397 (1): 91-98. CrossRef
Dicter N, Madar Z, Tirosh O: Alpha-lipoic acid inhibits glycogen synthesis in rat soleus muscle via its oxidative activity and the uncoupling of mitochondria. J Nutr. 2002, 132 (10): 3001-3006. PubMed
Rouchette L, Ghibu S, Richard C, Zeller M, Cottin Y, Vergely C: Direct and indirect antioxidant properties of α -lipoic acid. Mol Nutr Food Res. 2013, 57: 114-125. CrossRef
Dinkova-kostova AT, Talalay P: Direct and indirect antioxidant properties of inducers of cytoprotective proteins. Mol Nutr Food Res. 2008, 52: S128-S138. PubMed
Bierhaus A, Chevion S, Chevion M, Hofmann M, Quehenberger P, Illmer T, Luther T, Berentshtein E, Tritschler H, Müller M, Wahl P, Ziegler R, Nawroth PP: Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes. 1997, 46 (9): 1481-1490. PubMedCrossRef
Zembron-Lacny A, Gajeswski M, Naczac M, Dziewiecka H, Siatkkowski I: Physical activity and alpha-lipoic acid modulate inflammatory response through changes in thiol redox status. J Physiolo. 2013, 69: 397-404.
Sola S, Mir MQ, Cheema FA, Khan-Merchant N, Menon RG, Parthasarathy S, Khan BV: Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation. 2005, 111 (3): 343-348. PubMedCrossRef
Wang Y, Li X, Guo Y, Chan L, Guan X: Alpha-Lipoic acid increases energy expenditure by enhancing adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor-gamma coactivator-1alpha signaling in the skeletal muscle of aged mice. Metabolism. 2010, 59 (7): 967-976. PubMedCentralPubMedCrossRef
Koh G, Yang EJ, Kim MK, Lee SA, Lee DH: Alpha-lipoic acid treatment reverses 2-deoxy-D-ribose-induced oxidative damage and suppression of insulin expression in pancreatic β-cells. Biol Pharm Bull. 2013, [Epub ahead of print]. doi:10.12478/bpb.13-00292
Zhang Y, Han P, Wu N, He B, Lu Y, Li S, Liu Y, Zhao S, Liu L, Li Y: Amelioration of lipid abnormalities by α-lipoic acid through antioxidative and anti-inflammatory effects. Obesity (Silver Spring). 2011, 19 (8): 1647-1653. CrossRef
Koh EH, Lee WJ, Lee SA, Kim EH, Cho EH, Jeong E, Kim DW, Kim MS, Park JY, Park KG, Lee HJ, Lee IK, Lim S, Jang HC, Lee KH, Lee KU: Effects of alpha-lipoic acid on body weight in obese subjects. Am J Med. 2011, 124: 85.e1-85.e8. CrossRef
Ratliff JC, Palmese LB, Reutenauer EL, Tek C: An open-label pilot trial of alpha-lipoic acid for weight loss in patients with schizophrenia without diabetes. Clin Schizophr Relat Psychoses. 2013, 7: 1-13. Jose516 @ hotmail.com
Lean MEJ: Sibutramine: a review of clinical efficacy. In J Obes. 1997, 21: 30S-36S.
Gurvits GE, Tan A: Burning mouth syndrome. World J Gastroenterol. 2013, 7: 665-672. CrossRef
Femiano F: Burning mouth syndrome (BMS): an open trial of comparative efficacy of alpha-lipoic acid (thioctic acid) with other therapies. Minerva Stomatol. 2002, 51: 405-409. PubMed
McMackin CJ, Widlansky ME, Hamburg NM, Huang AL, Weller S, Holbrook M, Gokce N, Hagen TM, Keaney JF, Vita JA: Effect of combined treatment with alpha-Lipoic acid and acetyl-L-carnitine on vascular function and blood pressure in patients with coronary artery disease. J Clin Hypertens (Greenwich). 2007, 9 (4): 249-255. CrossRef
Durand M, Mach N: Alpha lipoic acid and its antioxidant against cancer and diseases of central sensitization. Nutr Hosp. 2013, 28: 1031-1038. PubMed
Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, Murgia V, Camboni P, Ferreli L: The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression. Free Radic Res. 2003, 37 (2): 213-223. PubMedCrossRef
Guais A, Baronzio G, Sanders E, Campion F, Mainini C, Fiorentini G, Montagnani F, Behzadi M, Schwartz L, Abolhassani M: Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report. Invest New Drugs. 2012, 30: 200-211. PubMedCrossRef
Polat B, Halici Z, Cadirci E, Albayrak A, Karakus E, Bayir Y, Bilen H, Sahin A, Yuksel TN: The effect of alpha-lipoic acid in ovariectomy and inflammation-mediated osteoporosis on the skeletal status of rat bone. Eur J Pharmacol. 2013, doi:S0014-2999 (13)00555-4. 10.1016
Skyler J, Oddo C: Diabetes trends in the USA. Diabetes Metab Res Ver. 2002, 18: S21-S26. CrossRef
The Diabetes Control and Complications Trial Study Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med. 1993, 329: 977-986. CrossRef
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with diabetes type 1. N Engl J Med. 2005, 353: 2643-2653. CrossRef
Stratton IM, Adler AI, Neil AW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR, on behalf of the UK Prospective Diabetes Study Group: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000, 321: 405-412. PubMedCentralPubMedCrossRef
Gomes MB, de Mattos Matheus AS, Calliari LE, Luescher JL, Manna TD, Savoldelli RD, Cobas RA, Coelho WS, Tschiedel B, Ramos AJ, Fonseca RM, Araujo NB, Almeida HG, Melo NH, Jezini DL, Negrato CA: Economic status and clinical care in young type 1 diabetes patients: a nationwide multicenter study in Brazil. Acta Diabetol. 2013, 50 (5): 743-752. Epub 2012 Jun 12 PubMedCrossRef
Gomes MB, Giannella-Neto D, Faria M, Tambascia MA, Fonseca RM, Rea RR, Macedo G, Modesto Filho J, Schmid H, Bittencourt AV, Cavalcanti S, Rassi N, Pedrosa H, Atala Dib S: Prevalence of type 2 diabetic patients within the targets of care guidelines in daily clinical practice: a multicenter study in Brazil. Rev Diabet Stud. 2006, 3: 82-87. PubMedCrossRef
American Diabetes Association: Economic costs of diabetes in the US in 2007. Diabetes Care. 2008, 31: 596-615. CrossRef
Ruderman NB, Williamson JR, Brownlee M: Glucose and diabetic vascular disease. FASEB J. 1992, 6 (11): 2905-2914. PubMed
Porasuphatana S, Suddee S, Nartnampong A, Konsil J, Harnwong B, Santaweesuk A: Glycemic and oxidative status of patients with type 2 diabetes mellitus following oral administration of alpha- lipoic acid: a randomized double-blinded placebo-controlled study. Asia Pac J Clin Nutr. 2012, 21 (1): 12-21. PubMed
de Oliveira AM, Rondó PH, Luzia LA, D’Abronzo FH, Illison VK: The effects of lipoic acid and α-tocopherol supplementation on the lipid profile and insulin sensitivity of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Diabetes Res Clin Pract. 2011, 92 (2): 253-260. PubMedCrossRef
Borcea V, Nourooz-Zadeh J, Wolff SP, Klevesath M, Hofmann M, Urich H, Wahl P, Ziegler R, Tritschler H, Halliwell B, Nawroth PP: alpha- Lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuria. Free Radic Biol Med. 1999, 26 (11–12): 1495-1500. PubMedCrossRef
Morcos M, Borcea V, Isermann B, Gehrke S, Ehret T, Henkels M, Schiekofer S, Hofmann M, Amiral J, Tritschler H, Ziegler R, Wahl P, Nawroth PP: Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Diabetes Res Clin Pract. 2001, 52 (3): 175-183. PubMedCrossRef
Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G: Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care. 1997, 20 (3): 369-373. PubMedCrossRef
Pop-Busui R, Stevens MJ, Raffel DM, White EA, Mehta M, Plunkett CD, Brown MB, Feldman EL: Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial. Diabetologia. 2013, 56 (8): 1835-1844. PubMedCentralPubMedCrossRef
Ziegler D: Diagnosis and mangement of diabetic peripheral neuropathy. Diabet Med. 1996, 13 (suppl 1): S34-S38. PubMed
Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Möller W, Tritschler HJ, Mehnert H: Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res. 1999, 31 (3): 171-179. PubMedCrossRef
Ziegler D, Hanefeld M, Ruhnau KJ, Hasche H, Lobisch M, Schütte K, Kerum G, Malessa R: Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care. 1999, 22 (8): 1296-1301. PubMedCrossRef
Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, Low PA, Nehrdich D, Novosadova M, O’Brien PC, Reljanovic M, Samigullin R, Schuette K, Strokov I, Tritschler HJ, Wessel K, Yakhno N, Ziegler D, SYDNEY Trial Study Group: The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 2003, 26 (3): 770-776. PubMedCrossRef
Ziegler D, Low PA, Litchy WJ, Boulton AJ, Vinik AI, Freeman R, Samigullin R, Tritschler H, Munzel U, Maus J, Schütte K, Dyck PJ: Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011, 34 (9): 2054-2060. PubMedCentralPubMedCrossRef
Bertolloto F, Massome A: Combination of alpha lipoic acid and superoxide dismutase leads to physiological and symptomatic improvements in diabetic neuropathy. Drugs. 2012, 12: 29-34.
Vasudevan D, Naik MM, Mukaddam QI: Efficacy and safety of methylcobalamin, alpha lipoic acid and pregabalin combination versus pregabalin monotherapy in improving pain and nerve conduction velocity in type 2 diabetes associated impaired peripheral neuropathic condition. Results of a pilot study. Ann Indian Acad Neurol. 2014, 17: 19-24. doi:10.4103/0972-2327.128535 PubMedCentralPubMedCrossRef
- Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases
Marilia Brito Gomes
Carlos Antonio Negrato
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II